Legal Use of Peptides as an APRN

Abstract

Peptide therapy has become an important topic in metabolic health, hormone care, weight management, recovery, and integrative medicine. However, the word "peptide" does not automatically mean that a product is legal, FDA-approved, safe, or appropriate for human treatment. Legal peptide use depends on the specific product, its FDA status, how it is prescribed or compounded, the patient's medical needs, and the laws of the state where care is provided.

In an integrative clinic, peptide-related medical care may be coordinated with chiropractic care, rehabilitation, nutrition, exercise, and functional medicine. The medical provider evaluates the patient, determines whether prescription treatment is appropriate, and manages medications. The chiropractor focuses on biomechanics, movement, musculoskeletal function, and rehabilitation. When these roles are clearly separated but coordinated, patients can receive a more complete approach to health and recovery.

What Does "Legal Peptide Use" Mean?

Peptides are short chains of amino acids. Some naturally occur in the human body and act as signals that help regulate metabolism, hormones, appetite, tissue activity, and other biological functions. Insulin is one familiar example of a peptide-based medicine.

However, legal peptide therapy is more complex than simply asking whether peptides are legal.

In the United States, a peptide used to diagnose, prevent, manage, or treat a medical condition generally falls within federal drug regulation. Some peptide-based drugs have received FDA approval. Other products may be FDA-approved drugs prescribed for off-label use. Still others may be prepared as compounded medications when federal and state requirements are met (FDA, 2026a; Holt, 2026).

This creates several important categories:

FDA-approved peptide medications: These have undergone FDA review for specific uses.
Off-label use of an FDA-approved medication: A licensed clinician may sometimes prescribe an approved drug for another medically appropriate use. FDA has not approved that particular use, so clinical judgment and scientific support are important.
Compounded medications: These are prepared for specific medical needs under federal and state compounding laws. A compounded drug itself is not FDA-approved.
Investigational or research peptides: Products labeled "research use only" or "not for human consumption" are not automatically legal for clinical treatment simply because they can be purchased online.

The FDA states that compounded drugs do not undergo the same premarket review for safety, effectiveness, and quality as FDA-approved products (FDA, 2026a).

Compounding Does Not Automatically Make a Peptide Legal

One of the most common misunderstandings is that a peptide becomes legal for patient treatment if a compounding pharmacy is willing to sell it.

That is not necessarily true.

Federal Sections 503A and 503B limit which bulk drug substances can be used in compounding. The FDA continues to evaluate these substances, and regulatory status can change (FDA, 2026b; LumaLex Law, 2026).

BPC-157 is a useful example of why clinicians should avoid relying on old internet lists. In July 2026, the FDA's Pharmacy Compounding Advisory Committee considered BPC-157-related substances for possible inclusion on the Section 503A bulk substances list. Advisory committee recommendations are not final FDA action. The FDA has also published safety concerns related to BPC-157, including limited human safety information and possible peptide-related impurities and immune reactions.

Therefore, a clinician should verify the current status of an individual peptide before prescribing, ordering, advertising, or administering it.

What the New Mexico Board of Nursing Says About Peptide Therapy

The September 2026 New Mexico Board of Nursing FAQ provides a useful example of how a state nursing board approaches this changing field. Importantly, the Board clearly states that its FAQ is informational, is not a legal opinion, and cannot be cited as legal authority.

The document explains that APRNs must practice according to their education, experience, population focus, prescriptive authority, and professional competency. A valid provider-patient relationship should include an appropriate history and physical examination, treatment plan, informed consent, clinical justification, and appropriate follow-up.

For compounded medications, the New Mexico guidance emphasizes:

Confirming that compounding is legally permitted
Working with appropriately licensed pharmacies
Telling patients when a medication is compounded rather than an FDA-approved manufactured product
Documenting why the compounded medication is needed
Avoiding unverified or noncompliant sources

The Board also recommends appropriate history, medication review, evaluation of contraindications, physical examination, laboratory testing when indicated, informed consent, documentation, and ongoing monitoring.

These are useful safety principles, but New Mexico Board rules do not determine how a Texas clinic operates.

Texas Scope of Practice Matters in an El Paso Clinic

For a clinic in El Paso, Texas law is especially important.

Texas law specifically states that chiropractic practice does not include prescribing controlled substances, dangerous drugs, or other prescription drugs. Therefore, you cannot prescribe peptides under a Texas chiropractic license (Tex. Occ. Code § 201.002).

That distinction matters when a professional holds more than one license.

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, practices with both chiropractic and advanced nursing credentials. When providing chiropractic services, he focuses on the musculoskeletal system, biomechanics, nonsurgical care, rehabilitation, and related chiropractic functions. Prescription decisions must instead be performed under the appropriate medical or APRN authority.

Texas law permits physicians to delegate prescriptive authority to qualified APRNs through a prescriptive authority agreement, provided they meet statutory requirements. The Texas Board of Nursing also explains that APRN prescriptive authority depends on the APRN's role, population focus, education, competency, physician delegation, and written agreement (Texas Board of Nursing [TBON], 2026).

In other words, the license being used matters.

A Multidisciplinary Model at Injury Medical Clinic PA

At Injury Medical Clinic PA in El Paso, the multidisciplinary structure brings together chiropractic, advanced practice nursing, internal medicine oversight, functional medicine, personal injury care, and rehabilitation.

Public provider records identify Maria Guadalupe Cardenas, MD, NPI 1164426749, Texas medical license J2933, as an internal medicine physician in El Paso. Clinic materials describe Dr. Cardenas as board-certified in internal medicine, with more than four decades of experience, and as the practice's medical director and collaborative physician.

Within this model, medical oversight and chiropractic rehabilitation can have different but complementary responsibilities.

Dr. Cardenas provides internal medicine expertise and medical direction. Dr. Jimenez brings his combined experience in chiropractic, family nurse practitioner practice, functional medicine, musculoskeletal care, and injury rehabilitation.

This coordinated model can keep medical prescribing decisions separate from chiropractic procedures while allowing the professionals to communicate about the same patient's overall plan.

How Chiropractic Care Fits With Medically Managed Peptide Therapy

Chiropractic care should not be described as making peptide medication "work better." There is not enough evidence to make that claim.

Instead, the two approaches may address different parts of a patient's recovery plan.

Integrative chiropractic care can focus on:

Joint and spinal biomechanics
Mobility and range of motion
Progressive rehabilitation
Muscle balance and functional strength
Exercise tolerance
Movement patterns after injury
Returning to work, activity, or sports

Medical management may address metabolic disease, obesity, hormonal concerns, or another diagnosis for which an appropriate peptide-based medication is being considered.

This distinction is especially important during GLP-1 treatment. The New Mexico Board guidance emphasizes adequate protein, resistance exercise, preservation of lean body mass, vitamins and nutrients, and long-term lifestyle changes. Failure to protect muscle mass can contribute to sarcopenia and poor long-term outcomes.

Chiropractic rehabilitation can therefore complement medical weight-management treatment by helping patients remain active, improve movement, progressively strengthen muscles, and manage musculoskeletal barriers to exercise.

Clinical Observations From Dr. Alexander Jimenez

In his published clinical observations, Dr. Alexander Jimenez describes peptide therapy as one possible component of a larger integrative plan rather than a stand-alone answer. His clinical model combines medical evaluation with rehabilitation, chiropractic biomechanics, nutrition, laboratory assessment, movement, and lifestyle support (Jimenez, 2026a, 2026b).

This approach is also reflected in other integrative medicine and chiropractic discussions. Peptides are often presented alongside resistance training, manual care, nutrition, sleep, and rehabilitation rather than as a replacement for these basic recovery tools (Evolution Integrative Medicine, 2026; ProCredits, 2025).

The most important clinical principle is coordination. A medication cannot correct poor biomechanics by itself. Likewise, a spinal adjustment cannot replace appropriate medical management of diabetes, obesity, endocrine disease, or another medical condition.

A Safer Peptide Therapy Process

A responsible integrative clinic should begin with the patient rather than with a particular peptide.

The process may include a complete medical and medication history, examination, appropriate laboratory testing, identification of contraindications, discussion of FDA approval status, review of alternatives, informed consent, pharmacy verification, and a documented monitoring plan.

Patients should also understand whether the medication is:

FDA-approved for the condition being treated,
FDA-approved but being used off-label,
lawfully compounded for an individual medical need, or
investigational and outside routine clinical treatment.

Products purchased from online "research peptide" sellers should not be confused with prescription medications prepared through legitimate medical and pharmacy channels. Federal regulators and healthcare attorneys continue to warn that "research use only" labeling does not permit marketing an unapproved product for human treatment (ByrdAdatto, 2026; Holt, 2026).

The Goal: Legal, Coordinated, Patient-Centered Care

Peptide science continues to develop rapidly. That makes careful medical judgment more important, not less important.

At an integrative practice such as Injury Medical Clinic PA, the goal is not simply to offer the newest therapy. A better approach is to determine whether a treatment is medically appropriate, legally available, supported by reasonable evidence, obtained through a legitimate source, and properly monitored.

Dr. Jimenez's chiropractic and rehabilitation approach can address movement, strength, spinal and joint mechanics, injury recovery, and functional health. Dr. Cardenas' internal medicine leadership provides another level of medical oversight. When appropriate APRN authority is used for medical evaluation and prescribing, these services can be coordinated with functional medicine, personal injury treatment, rehabilitation, nutrition, and other medically appropriate care.

The result is a multidisciplinary model in which medical treatment addresses medical needs while chiropractic care addresses biomechanics and musculoskeletal function. That clear division of responsibility is one of the most important parts of responsible integrative healthcare.